<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:   Device for the Activation of Nanoparticle-Based Cancer Therapies</AwardTitle>
<AwardEffectiveDate>02/15/2006</AwardEffectiveDate>
<AwardExpirationDate>04/30/2008</AwardExpirationDate>
<AwardTotalIntnAmount>0.00</AwardTotalIntnAmount>
<AwardAmount>500000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Gregory T. Baxter</SignBlockName>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase II project aims at developing a minimally invasive, image-guided cancer therapy for the optimum activation of nanoparticle based, photo-thermal cancer therapies. This will allow for the treatment of deep-seated tumor, irregular shaped tumors as well as regional metastatic spread and tumors situated near or within sensitive tissues.&lt;br/&gt;&lt;br/&gt;This technology will impact the current therapies for cancers, especially those of the brain and other sensitive areas.  The technology will provide a minimally invasive therapy with a high safety profile that allows treatment of poorly defined tumors margins without damage to surrounding, often sensitive tissues. This would make the treatment not only more effective but will also limit damage to healthy tissue and as such, limit side effects and other organ dysfunction. Additionally, this therapy is compatible with and potentially synergist with existing treatment modalities.&lt;br/&gt;</AbstractNarration>
<MinAmdLetterDate>02/07/2006</MinAmdLetterDate>
<MaxAmdLetterDate>12/18/2007</MaxAmdLetterDate>
<ARRAAmount/>
<AwardID>0548741</AwardID>
<Investigator>
<FirstName>Jon</FirstName>
<LastName>Schwartz</LastName>
<EmailAddress>JSchwartz@Nanospectra.com</EmailAddress>
<StartDate>01/24/2007</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Jianxia</FirstName>
<LastName>Qiu</LastName>
<EmailAddress>JQiu@Nanospectra.com</EmailAddress>
<StartDate>02/07/2006</StartDate>
<EndDate>01/24/2007</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>NANOSPECTRA BIOSCIENCES, INC.</Name>
<CityName>HOUSTON</CityName>
<ZipCode>770544654</ZipCode>
<PhoneNumber>7138422720</PhoneNumber>
<StreetAddress>8285 EL RIO ST STE 150</StreetAddress>
<CountryName>United States</CountryName>
<StateName>Texas</StateName>
<StateCode>TX</StateCode>
</Institution>
<FoaInformation>
<Code>0116000</Code>
<Name>Human Subjects</Name>
</FoaInformation>
<FoaInformation>
<Code>0203000</Code>
<Name>Health</Name>
</FoaInformation>
<FoaInformation>
<Code>0510402</Code>
<Name>Biomaterials-Short &amp; Long Terms</Name>
</FoaInformation>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>9102</Code>
<Text>WOMEN, MINORITY, DISABLED, NEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
</Award>
</rootTag>
